Is QTTB or RANI more undervalued in 2026?

CirclFi compares Q32 Bio Inc. (QTTB) and Rani Therapeutics Holdings, Inc (RANI) using 13 institutional-grade valuation models. QTTB has a Quality of Company score of 7.5/10 while RANI scores 6.0/10.

Which is a better buy — QTTB or RANI?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do QTTB and RANI valuations compare?

QTTB at $11.05 and RANI at $0.95 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

QTTB vs RANI Valuation Comparison 2026 — Intrinsic Value Analysis

QTTB

Pharmaceutical Preparations

Q32 Bio Inc.

Quality

7.5

out of 10

Value Trap

SAFE

Price

$11.05

Last close

Models

12/13

Active

RANI

Pharmaceutical Preparations

Rani Therapeutics Holdings, Inc

Quality

6.0

out of 10

Value Trap

SAFE

Price

$0.95

Last close

Models

6/13

Active

Model-by-Model Comparison

Model	Type	QTTB Fair Value	QTTB Upside	RANI Fair Value	RANI Upside
Bayesian DCF	Intrinsic	$11.10	+0.5%	$0.22	-76.6%
Earnings Power Value	Intrinsic	$9.81	-11.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$4.45	-59.7%	$0.37	-60.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for QTTB vs RANI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

QTTB vs RANI — Which Stock Is More Undervalued?

QTTB scores higher with a 7.5/10 quality rating vs RANI's 6.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Q32 Bio Inc. (QTTB) and Rani Therapeutics Holdings, Inc (RANI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

QTTB currently trades at $11.05 with a QOC of 7.5/10, while RANI trades at $0.95 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).